http://www.zibb.com/all/theme/cq/Serono+SA Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Wed, 25 Nov 2009 23:08:31 GMTWed, 25 Nov 2009 23:08:31 GMT608831http://www.zibb.com/all/theme/cq/Serono+SA http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.merck.de/servlet/PB/menu/1526170/index.htmlNews on Acquisition of Serono SA 2007/04/05 Merck Serono to Voluntarily Delist and Deregister Its Bearer Shares and American Depositary Shares 2007/03/21 Merck Initiates Squeeze Out Procedure for Shares of Merck Serono S.A. Merck Serono Confirms Previously Announced 2006 Figures 2007/02/23 Merckhttp://www.merck.de/servlet/PB/menu/1526170/index.htmlSerono SAhttp://www.biz-lib.com/ZPH98448.htmlPartneringdesk Serono S.A. and Company Deals Briefing is a business development and licensing report written to support your partnering and strategic decisions.http://www.biz-lib.com/ZPH98448.htmlSerono SAhttp://www.researchandmarkets.com/reports/307733Serono SA Deals Briefing provides an in-depth view of the 38 deals made by Serono SA and its subsidiaries with 37 partnering companies between 2001 and 2006, in a clear and accessible PDF format.http://www.researchandmarkets.com/reports/307733Serono SAhttp://www.lse.co.uk/ShareChart.asp?ShareChart=SBIClick Here Click Here Life Style Extra - Finance, News & Entertainment Google Web www.lse.co.uk Life Style Extra Lines Home | Finance | News | Lifestyle | Chat Forums new - Life Style Extra Chat Forums! | Contact Register / Login Life Style Extra Lines 28 January 2007 - 16:04:29 BST Home : Financehttp://www.lse.co.uk/ShareChart.asp?ShareChart=SBISerono SAhttp://www.quotelinks.com/companies/sra.htmlStock quotes, news and charts for Serono S.A. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/sra.htmlSerono SAhttp://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2For the fiscal year ended December 2004, the company generated revenues of $2.5 billion up 21.8% from the previous year. Net income was up 26.7% to 494.2 million.http://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2Serono SAhttp://www.piribo.com/publications/pharmaceutical_companies/serono_sa_deals.htmlPartneringdesk Serono SA Deals briefing provides a comprehensive summary of the deals and alliances announced by the company and its subsidiaries between January 2000 and July 2005.http://www.piribo.com/publications/pharmaceutical_companies/serono_sa_deals.htmlSerono SAhttp://www.hoovers.com/serono/--ID__90988--/freeuk-co-factsheet.xhtmlFertile minds at Serono help women and men around the world combat infertility. One of the world's top biotechs, Serono focuses on recombinant genetic engineering to develop drugs. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its reproductive product line.http://www.hoovers.com/serono/--ID__90988--/freeuk-co-factsheet.xhtmlSerono SAhttp://www.ishareowner.com/csr/profile.cgi?id=6936Home | News | Reports | Marketplace | About Us | Contact | Tools | Login Corporate Social Research | Mutual Funds | Shareowner Action | Community Investment © SRI World Group, Inc.http://www.ishareowner.com/csr/profile.cgi?id=6936Serono SAhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=45575/PRNewswire-FirstCall/ -- Following the successful closing of the Share Purchase Agreement (SPA) and the resolutions passed during the Extraordinary General Meeting of Serono S.A.(1), Merck KGaA today announced the official launch of Merck Serono S.A. (virt-x: SEO and NYSE:SRA).http://www.pharmacychoice.com/News/article.cfm?Article_ID=45575Serono SAhttp://www.farmasel.nl/xcms/vacature/id/3603De opdrachtgeverMerck Serono is the division of Merck KGaA specialized in innovative prescription pharmaceuticals. Headquartered in Geneva, the division was established on January 5, 2007, following the acquisition of Serono S.A. (now Merck Serono S.A.http://www.farmasel.nl/xcms/vacature/id/3603Serono SAhttp://www.ftc.gov/os/2002/07/amgenanalysis.htmThe Federal Trade Commission ("Commission") has accepted, subject to final approval, an agreement containing a proposed Consent Order from Amgen Inc.http://www.ftc.gov/os/2002/07/amgenanalysis.htmSerono SAhttp://www.schuchardt.de/servlet/PB/menu/1753800_ePRJ-MERCK-EN-COME2MERCK-INTERNATIONAL_pcontent_l2_yno/content.html, is an affiliate of Merck Serono S.A. It is a fully integrated site including both active ingredient (biotech cell culture and purification) and fill, finish and packaging production activities. The facility is involved in the manufacturing of the division’s eight recombinant products.http://www.schuchardt.de/servlet/PB/menu/1753800_ePRJ-MERCK-EN-COME2MERCK-INTERNATIONAL_pcontent_l2_yno/content.htmlSerono SAhttp://www.verantwortung.merck.de/servlet/PB/menu/1526170/index.htmlNews on Acquisition of Serono SA 2007/01/05 Merck KGaA Acquires Majority Shareholding in Serono S.A. 2006/12/18 Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono 2006/11/24 Merck KGaA completes Financing of Serono Acquisition 2006/09/25 Merck KGaA mandates Bear Stearns,http://www.verantwortung.merck.de/servlet/PB/menu/1526170/index.htmlSerono SAhttp://www.merck-pigmente.de/servlet/PB/menu/1526170/index.htmlNews on Acquisition of Serono SA 2007/01/09 Merck KGaA Announces Public Tender Offer for Merck Serono Shares Public Tender Offer (English) Fairness Opinion (English) Offre publique d’acquisition (Français) Attestation d’équité (Français) 2007/01/08 Merck Serono Is Launched 2007/01/05 Merck KGaAhttp://www.merck-pigmente.de/servlet/PB/menu/1526170/index.htmlSerono SAhttp://www.zymogenetics.com/ir/sec-page.php?id=2988710&doc=2&num=1Exhibit 99.1 ZymoGenetics and Serono Establish Broad Strategic Research, Development and Commercialization Alliance SEATTLE & GENEVA--(BUSINESS WIRE)--Sept. 8, 2004-- Serono and ZymoGenetics to collaborate in the development of novel protein and antibody therapeutics ZymoGenetics, Inc.http://www.zymogenetics.com/ir/sec-page.php?id=2988710&doc=2&num=1Serono SAhttp://www.merck.de/servlet/PB/menu/1656670_ePRJ-MERCKSERONO-EN-INTERNET_pcontent_l2_yno/content.htmlMerck Serono is the division of Merck KGaA specialized in innovative prescription pharmaceuticals. Headquartered in Geneva, the division was established on January 5, 2007, following the acquisition of Serono S.A. (now Merck Serono S.A.http://www.merck.de/servlet/PB/menu/1656670_ePRJ-MERCKSERONO-EN-INTERNET_pcontent_l2_yno/content.htmlSerono SAhttp://www.researchandmarkets.com/reports/1198Datamonitors Merck KgaA PharmaVitae report is a one-stop source of qualitative and quantitative company and product analysis. Benefit from a breadth and depth of company and market coverage, unrivalled by competitor profiles and uniquely providing product forecasts and analysis in one document.http://www.researchandmarkets.com/reports/1198Serono SAhttp://www.researchandmarkets.com/reports/1191Datamonitors Merck and Co. PharmaVitae report is a one-stop source of qualitative and quantitative company and product analysis. Benefit from a breadth and depth of company and market coverage, unrivalled by competitor profiles and uniquely providing product forecasts and analysis in one document.http://www.researchandmarkets.com/reports/1191Serono SAhttp://www.researchandmarkets.com/reports/74396Introduction This analysis examines the current position and future outlook for Merck & Co. in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-7 year sales forecasts for key drugs.http://www.researchandmarkets.com/reports/74396Serono SAhttp://www.researchandmarkets.com/reports/307736Sanofi-Aventis Deals Briefing provides an in-depth view of the 158 deals made by Sanofi-Aventis and its subsidiaries with 165 partnering companies between 2001 and 2006, in a clear and accessible PDF format.http://www.researchandmarkets.com/reports/307736Serono SAhttp://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2&CType=ViewA statement by Ernesto Bertarelli, Chief Executive Officer of Serono SA, follows. This statement has been taken from the company’s 2002 Annual Report. 2002 has been a pivotal year in the development of Serono.http://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2&CType=ViewSerono SAhttp://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2&CType=CompetitorTo receive a complete and bespoke profile on Serono SA, including SWOT analysis, order the full profile for just $125. The full profile of Serono SA also contains details of the company's key executives and provides summary analysis of its major revenue lines and strategy.http://www.computerbusinessreview.com/companyprofile.asp?guid=69DDE48B-45E8-4E05-B1ED-4901168492F2&CType=CompetitorSerono SAhttp://www.researchandmarkets.com/reports/4561/pharmavitae_2002_merck_and_coThis analysis examines the current position and future outlook for Merck in the ethical pharmaceutical sector. It encompasses company strategy, comparative portfolio and pipeline analysis and assessment of financial performance, providing 1, 3 and 6 year sales forecasts for key drugs.http://www.researchandmarkets.com/reports/4561/pharmavitae_2002_merck_and_coSerono SAhttp://www.researchandmarkets.com/reports/586571/merck_serono_s_a_pharmavitae_profileThis analysis examines the historical and forecast performance for Merck-Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.http://www.researchandmarkets.com/reports/586571/merck_serono_s_a_pharmavitae_profileSerono SA